Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 3
1986 6
1987 4
1988 7
1989 4
1990 4
1991 5
1992 4
1993 5
1994 4
1995 6
1996 14
1997 16
1998 14
1999 29
2000 25
2001 23
2002 32
2003 40
2004 39
2005 40
2006 69
2007 71
2008 63
2009 102
2010 135
2011 151
2012 167
2013 177
2014 191
2015 235
2016 240
2017 279
2018 303
2019 372
2020 453
2021 497
2022 550
2023 167
Text availability
Article attribute
Article type
Publication date

Search Results

4,079 results
Results by year
Filters applied: . Clear all
Page 1
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. Among authors: xue l. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.
Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, Wei W, Li G, Cheng X, Xue L, Li Y, Chen H, Wei S, Sun R, Cui H, Meng Y, Liu M, Li Y, Feng R, Yu X, Zhu R, Wu Y, Li L, Yang B, Ma Y, Wang J, Zhu W, Deng D, Xi Y, Wang F, Li H, Guo S, Zhuang X, Wang X, Jiao Y, Cui Y, Zhan Q. Liu Z, et al. Among authors: xue l. Cancer Cell. 2023 Jan 9;41(1):181-195.e9. doi: 10.1016/j.ccell.2022.12.004. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584672
Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J, Jiang W, Mu H, Ma X, Yin F, Lin J, Wang C, Yu S, Jiang L, Lv G, Liu F, Xue L, Tian K, Wang G, Zhou Z, Lv Y, Wang Z, Zhang T, Xu J, Yang L, Zhao K, Sun W, Tang Y, Cai Z, Wang S, Hua Y. Jiang Y, et al. Among authors: xue l. Nat Commun. 2022 Nov 23;13(1):7207. doi: 10.1038/s41467-022-34689-5. Nat Commun. 2022. PMID: 36418292 Free PMC article.
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X, Xue L, Ding X, Zhang J, Jiang L, Liu S, Hou H, Jiang B, Cheng L, Zhu Q, Zhang L, Zhou X, Ma J, Liu Q, Li Y, Ren Z, Jiang B, Song X, Song J, Jin W, Wei M, Shen Z, Liu X, Wang L, Li K, Zhang T. Chen X, et al. Among authors: xue l. Front Immunol. 2022 Feb 22;13:828319. doi: 10.3389/fimmu.2022.828319. eCollection 2022. Front Immunol. 2022. PMID: 35273608 Free PMC article.
4,079 results